文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

巴雷特食管和胃食管反流患者患食管癌的风险。

Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux.

作者信息

Solaymani-Dodaran M, Logan R F A, West J, Card T, Coupland C

机构信息

University of Nottingham, Division of Epidemiology and Public Health, Queen's Medical Centre, Nottingham NG7 2UH, UK.

出版信息

Gut. 2004 Aug;53(8):1070-4. doi: 10.1136/gut.2003.028076.


DOI:10.1136/gut.2003.028076
PMID:15247170
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1774141/
Abstract

BACKGROUND AND AIMS: While patients with Barrett's oesophagus develop oesophageal adenocarcinoma more frequently than the general population, it has controversially been suggested that gastro-oesophageal reflux (GORD) itself is a more important determinant of risk. In order to assess the validity of this suggestion, we examined the risk of oesophageal cancer in patients with Barrett's and with GORD compared with the general population in a community based cohort study. METHODS: Cohorts of patients with Barrett's (n = 1677), oesophagitis (n = 6392), and simple reflux (n = 6328), and a reference cohort (n = 13416) were selected from the General Practice Research Database. The last three cohorts were matched to the Barrett's cohort by general practitioner practice, age, and sex. Cox's regression analysis was used to calculate relative risks for oesophageal cancer. Standardised incidence ratio methodology was used to estimate the relative risks for oesophageal adenocarcinoma. RESULTS: A total of 137 oesophageal cancers were identified, of which 94 prevalent cases were excluded. The hazard ratios for oesophageal cancer were 10.6 (5.1-22.0), 2.2 (0.9-5.2), and 1.7 (0.7-4.5) in the Barrett's, oesophagitis, and reflux cohorts compared with the reference cohort, respectively. The corresponding relative risks for oesophageal adenocarcinoma were 29.8 (9.6-106), 4.5 (1.04-19.6), and 3.1 (0.6-14.2). CONCLUSION: Barrett's oesophagus increases the risk of oesophageal cancer approximately 10 times and oesophageal adenocarcinoma approximately 30 times compared with the general population. There is only a modestly increased risk of oesophageal cancer in patients with reflux who have no record of Barrett's oesophagus. Our findings therefore do not support the suggestion that gastro-oesophageal reflux disease itself predisposes to cancer.

摘要

背景与目的:虽然巴雷特食管患者发生食管腺癌的频率高于普通人群,但有争议地认为胃食管反流(GORD)本身是更重要的风险决定因素。为了评估这一观点的正确性,我们在一项基于社区的队列研究中,比较了巴雷特食管患者、胃食管反流患者与普通人群患食管癌的风险。 方法:从全科医疗研究数据库中选取了巴雷特食管患者队列(n = 1677)、食管炎患者队列(n = 6392)和单纯反流患者队列(n = 6328),以及一个对照队列(n = 13416)。后三个队列根据全科医生诊所、年龄和性别与巴雷特食管患者队列进行匹配。采用Cox回归分析计算食管癌的相对风险。使用标准化发病率比方法估计食管腺癌的相对风险。 结果:共识别出137例食管癌患者,其中94例现患病例被排除。与对照队列相比,巴雷特食管、食管炎和反流队列中食管癌的风险比分别为10.6(5.1 - 22.0)、2.2(0.9 - 5.2)和1.7(0.7 - 4.5)。食管腺癌的相应相对风险分别为29.8(9.6 - 106)、4.5(1.04 - 19.6)和3.1(0.6 - 14.2)。 结论:与普通人群相比,巴雷特食管使患食管癌的风险增加约10倍,患食管腺癌的风险增加约30倍。在没有巴雷特食管记录的反流患者中,患食管癌的风险仅适度增加。因此,我们的研究结果不支持胃食管反流病本身易患癌症的观点。

相似文献

[1]
Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux.

Gut. 2004-8

[2]
Risk of extra-oesophageal malignancies and colorectal cancer in Barrett's oesophagus and gastro-oesophageal reflux.

Scand J Gastroenterol. 2004-7

[3]
Risk of Barrett's oesophagus, oesophageal adenocarcinoma and reflux oesophagitis and the use of nitrates and asthma medications.

Scand J Gastroenterol. 2010-12

[4]
Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study.

Gut. 2008-10

[5]
Review article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus.

Aliment Pharmacol Ther. 2004-10

[6]
Multivariate analysis of the association of acid and duodeno-gastro-oesophageal reflux exposure with the presence of oesophagitis, the severity of oesophagitis and Barrett's oesophagus.

Gut. 2008-8

[7]
Barrett's oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation?

Gut. 2005-3

[8]
Dietary inflammatory index and risk of reflux oesophagitis, Barrett's oesophagus and oesophageal adenocarcinoma: a population-based case-control study.

Br J Nutr. 2017-5

[9]
The extent of oesophageal acid exposure overlap among the different gastro-oesophageal reflux disease groups.

Aliment Pharmacol Ther. 2006-1-15

[10]
Pathophysiological characteristics of the various forms of gastro-oesophageal reflux disease. Spectrum disease or distinct phenotypic presentations?

Dig Liver Dis. 2006-9

引用本文的文献

[1]
Chemoprevention of Barrett's Esophagus: a Systematic Review and Comprehensive Assessment of Bias.

Dis Esophagus. 2025-7-3

[2]
Increased Prevalence of Barrett's Esophagus in Taiwan: A Prospective Multicenter Study.

J Gastroenterol Hepatol. 2025-7

[3]
Long-term risk factors for developing Barrett's oesophagus in patients with gastro-oesophageal reflux disease: a longitudinal cohort study.

BMJ Open Gastroenterol. 2024-3-22

[4]
Risk factors for gastroesophageal reflux disease: a population-based study.

BMC Gastroenterol. 2024-2-5

[5]
Epigenetic Alterations from Barrett's Esophagus to Esophageal Adenocarcinoma.

Int J Mol Sci. 2023-4-25

[6]
Dietary and Nutritional Support in Gastrointestinal Diseases of the Upper Gastrointestinal Tract (I): Esophagus.

Nutrients. 2022-11-14

[7]
Epidemiology of stomach cancer.

World J Gastroenterol. 2022-3-28

[8]
Intrinsic Cellular Susceptibility to Barrett's Esophagus in Adults Born with Esophageal Atresia.

Cancers (Basel). 2022-1-20

[9]
Heritability and De Novo Mutations in Oesophageal Atresia and Tracheoesophageal Fistula Aetiology.

Genes (Basel). 2021-10-10

[10]
Dynamic switch of immunity and antitumor effects of metformin in rat spontaneous esophageal carcinogenesis.

Cancer Immunol Immunother. 2022-4

本文引用的文献

[1]
Risk of adenocarcinoma in Barrett's oesophagus: population based study.

BMJ. 2003-9-6

[2]
Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease.

Pharmacoepidemiol Drug Saf. 2002

[3]
Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation.

Am J Med. 2001-7

[4]
Correlation of oesophageal acid exposure with Barrett's oesophagus length.

Gut. 2001-3

[5]
Is there publication bias in the reporting of cancer risk in Barrett's esophagus?

Gastroenterology. 2000-8

[6]
Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries.

Int J Epidemiol. 2000-8

[7]
Socioeconomic status and risk of adenocarcinoma of the oesophagus and cancer of the gastric cardia in Scotland.

Br J Cancer. 2000-8

[8]
The significance of heartburn.

QJM. 2000-6

[9]
Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.

Am J Gastroenterol. 1999-12

[10]
The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry.

Am J Gastroenterol. 1999-8

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索